AKŞİT, E. Et Al. 2022. The importance of anti-fibrotic drugs as first-line therapy in patients with arrhythmogenic right ventricular dysplasia. INTERNATIONAL JOURNAL OF CARDIOLOGY , vol.353 , 53.

AKŞİT, E., KÜÇÜK, U., Taylan, G., Cinier, G., Karabay, C. Y., & Akgun, T., (2022). The importance of anti-fibrotic drugs as first-line therapy in patients with arrhythmogenic right ventricular dysplasia. INTERNATIONAL JOURNAL OF CARDIOLOGY , vol.353, 53.

AKŞİT, ERCAN Et Al. "The importance of anti-fibrotic drugs as first-line therapy in patients with arrhythmogenic right ventricular dysplasia," INTERNATIONAL JOURNAL OF CARDIOLOGY , vol.353, 53, 2022

AKŞİT, ERCAN Et Al. "The importance of anti-fibrotic drugs as first-line therapy in patients with arrhythmogenic right ventricular dysplasia." INTERNATIONAL JOURNAL OF CARDIOLOGY , vol.353, pp.53, 2022

AKŞİT, E. Et Al. (2022) . "The importance of anti-fibrotic drugs as first-line therapy in patients with arrhythmogenic right ventricular dysplasia." INTERNATIONAL JOURNAL OF CARDIOLOGY , vol.353, p.53.

@article{article, author={ERCAN AKŞİT Et Al. }, title={The importance of anti-fibrotic drugs as first-line therapy in patients with arrhythmogenic right ventricular dysplasia}, journal={INTERNATIONAL JOURNAL OF CARDIOLOGY}, year=2022, pages={53} }